- Home
- LUCD vs SCLX Comparison
LUCD vs SCLX Comparison
Compare LUCD & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | SCLX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 139.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCD | SCLX |
|---|---|---|
| Price | $1.01 | $18.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $3.88 | N/A |
| AVG Volume (30 Days) | ★ 646.2K | 137.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,399,000.00 | ★ $40,360,000.00 |
| Revenue This Year | $13.30 | $89.26 |
| Revenue Next Year | $155.58 | $203.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.01 | N/A |
| 52 Week Low | $0.75 | $3.60 |
| 52 Week High | $1.80 | $34.27 |
Technical Indicators
Market Signals| Indicator | LUCD | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 50.11 |
| Support Level | $1.00 | $19.43 |
| Resistance Level | $1.10 | $27.00 |
| Average True Range (ATR) | 0.06 | 2.27 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 7.20 | 29.49 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.